Clinical Trial Update: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ranibizumab injections versus sham in patients with macular edema due to branch retinal vein occlusion; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Macular Edema Secondary to Branch Retinal Vein Occlusion | Phase 3 | Status: COMPLETED | Results posted: 2017-05-08